Abstract
Cyclophosphamide, a new alkylating agent, was administered to 59 children with neoplastic disease. Long-term continuous therapy was employed. The drug dosage was adjusted by the white blood count since depression of granulocyte production occurred at doses that have little effect on erythrocyte and thrombocyte production. Alopecia and hemorrhagic cystitis were frequent. Temporary remissions occurred in patients with lymphomas and in 6 of 16 children with acute leukemia. There was temporary regression of tumor in patients with neuroblastoma, rhabdomyosarcoma, Ewing's sarcoma, and malignant teratoma. Cyclophosphamide seemed most useful for palliation or in combination with operation and/or radiation. The likelihood that cyclophosphamide alone will cure any of the diseases treated seems remote.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
